During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
Pfizer Inc. PFE
- Dividend Yield: 6.74%
- Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $28 to $30 on July 31. This analyst has an accuracy rate of 65%.
- Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and boosted the price target from $28 to $29 on May 2. This analyst has an accuracy rate of 67%.
- Recent News: On Nov. 20, Pfizer announced new Chief Scientific Officer and President, Research & Development.
- Benzinga Pro's real-time newsfeed alerted to latest PFE news.
Patterson Companies, Inc. PDCO
- Dividend Yield: 5.18%
- Baird analyst Jeff Johnson maintained a Neutral rating and cut the price target from $30 to $28 on Aug. 29. This analyst has an accuracy rate of 78%.
- Morgan Stanley analyst Erin Wright maintained an Equal-Weight rating and cut the price target from $35 to $28 on June 20. This analyst has an accuracy rate of 73%.
- Recent News: On Nov. 13, Patterson Dental extended strategic relationship with PDS Health.
- Benzinga Pro's real-time newsfeed alerted to latest PDCO news
CVS Health Corporation CVS
- Dividend Yield: 4.68%
- Truist Securities analyst David Macdonald reiterated a Buy rating and cut the price target from $76 to $67 on Nov. 20. This analyst has an accuracy rate of 67%.
- UBS analyst Kevin Celiendo maintained a Neutral rating and raised the price target from $60 to $62 on Nov. 7. This analyst has an accuracy rate of 79%.
- Recent News: On Nov. 18, CVS Health announced the addition of four new directors to its board.
- Benzinga Pro’s charting tool helped identify the trend in CVS stock.
Read More:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.